Macrophage migration inhibitory factor as an incriminating agent in dermatological disorders

Indian Journal of Dermatology

Volumn 58, Issue 2, 2013, Pages 157-

  Pazyar, Nader ^a   Feily, Amir ^b   Yaghoobi, Reza ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b JAHROM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cytokine; dermatology; inflammation; macrophage migration inhibitory factor; review

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR;

REVIEW; SKIN DISEASE;

EID: 84875736884     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.108068     Document Type: Review

References (49)

1. Dinarello CA. Proinflammatory cytokines. Chest 2000;118:503-8.
2. Shimizu T. Role of macrophage migration inhibitory factor (MIF) in the skin. J Dermatol Sci 2005;37:65-73.
3. Conroy H, Mawhinney L, Donnelly SC. Inflammation and cancer: macrophage migration inhibitory factor (MIF)-the potential missing link. QJM 2010;103:831-6.
4. Nishihira J. Novel pathophysiological aspects of macrophage migration inhibitory factor (review). Int J Mol Med 1998;2:17-28.
5. Wikimedia commons Available from: http://commons.wikimedia.org/wiki/File: Protein-MIF-PDB-1ca7. png# [Last accessed on 2012 Feb 22].
6. Bach JP, Rinn B, Meyer B, Dodel R, Bacher M. Role of MIF in inflammation and tumorigenesis. Oncology 2008;75:127-33.
7. Rossi AG, Haslett C, Hirani N, Greening AP, Rahman I, Metz CN, et al. Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J Clin Invest 1998; 101:2869-74.
8. Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996; 93:7849-54.
9. Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994; 179:1895-902.
10. Imamura K, Nishihira J, Suzuki M, Yasuda K, Sasaki S, Kusunoki Y, et al. Identification and immunohistochemical localization of macrophage migration inhibitory factor in human kidney. Biochem Mol Biol Int 1996; 40:1233-42.
11. Nishihira J, Koyama Y, Mizue Y. Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine 1998;10:199-205.
12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analysis of studies that evaluate health care interventions: explanation and elaboration. Ital J Public Health 2009,6:354-91.
13. Shimizu T, Ogata A, Honda A, Nishihira J, Watanabe H, Abe R, et al. Expression of macrophage migration inhibitory factor in rat skin during embryonic development. Exp Dermatol 2005;14:819-23.
14. Shimizu T, Ohkawara A, Nishihira J, Sakamoto W. Identification of macrophage migration inhibitory factor (MIF) in human skin and its immmunohistochemical localization. FEBS Lett 1996;381:199-202.
15. Yoshihisa Y, Makino T, Matsunaga K, Honda A, Norisugi O, Abe R, et al. Macrophage migration inhibitory factor is essential for eosinophil recruitment in allergen-induced skin inflammation. J Invest Dermatol 2011;131:925-31.
16. Yanagi T, Kodama K, Yoshihisa Y, Shimizu H, Shimizu T. Macrophage migration inhibitory factor in zinc-allergic systemic contact dermatitis. Cytokine 2006;35:270-4.
17. Goebeler M, Gutwald J, Roth J, Sorg C. The severity of irritant contact dermatitis in various strains of mice correlates with endothelial expression of migration inhibitory factor (MIF). Arch Dermatol Res 1991;283:246-50.
18. Malorny U, Goebeler M, Gutwald J, Roth J, Sorg C. Differences in migration inhibitory factor production by C57Bl/6 and BALB/c mice in allergic and irritant contact dermatitis. Int Arch Allergy Appl Immunol 1990;92:356-60.
19. Shimizu T, Abe R, Nishihira J, Shibaki A, Watanabe H, Nakayama T, et al. Impaired contact hypersensitivity in macrophage migration inhibitory factor-deficient mice. Eur J Immunol 2003;33:1478-87.
20. Shimizu T, Abe R, Ohkawara A, Mizue Y, Nishihira J. Macrophage migration inhibitory factor is an essential immunoregulatory cytokine in atopic dermatitis. Biochem Biophys Res Commun 1997;240:173-8.
21. Shimizu T, Abe R, Ohkawara A, Nishihira J. Increased production of macrophage migration inhibitory factor by PBMCs of atopic dermatitisJ Allergy Clin Immunol 1999;104:659-64.
22. Hamasaka A, Abe R, Koyama Y, Yoshioka N, Fujita Y, Hoshina D, et al. DNA vaccination against macrophage migration inhibitory factor improves atopic dermatitis in murine models. J Allergy Clin Immunol 2009;124:90-9.
23. Pazyar N, Yaghoobi R. Ginkgo biloba extract: A novel addition to antipsoriasis ammunition? J Altern Complement Med 2012;18:316-7.
24. Pazyar N, Yaghoobi R, Kazerouni A, Feily A. Oatmeal in dermatology: A brief review. Indian J Dermatol Venereol Leprol 2012;78:142-5.
25. Feily A, Pazyar N, Khazanee A, Ghassemi MR, Rafiee E, Safarpoor M. Potential advantages of topical phenytoin as a novel anti psoriasis arsenal. Niger J Med 2011;20:296-7.
26. Steinhoff M, Meinhardt A, Steinhoff A, Gemsa D, Bucala R, Bacher M. Evidence for a role of macrophage migration inhibitory factor in psoriatic skin disease. Br J Dermatol. 1999;141:1061-6.
27. Shimizu T, Nishihira J, Mizue Y, Nakamura H, Abe R, Watanabe H, et al. Histochemical analysis of macrophage migration inhibitory factor in psoriasis vulgaris. Histochem Cell Biol 2002;118:251-7.
28. Dimethylfumarate inhibits MIF-induced proliferation of keratinocytes by inhibiting MSK1 and RSK1 activation and by inducing nuclear p-c-Jun (S63) and p-p53 (S15) expression. Inflamm Res 2011;60:643-53.
29. Feily A, Pazyar N. Why vitiligo is associated with fewer risk of skin cancer?: Providing a molecular mechanism. Arch Dermatol Res 2011;303:623-4.
30. Serarslan G, Yönden Z, Söüt S, Sava N, Celik E, Arpaci A.Macrophage migration inhibitory factor in patients with vitiligo and relationship between duration and clinical type of disease. Clin Exp Dermatol 2010;35:487-90.
31. Shimizu T, Hizawa N, Honda A, Zhao Y, Abe R, Watanabe H, et al. Promoter region polymorphism of macrophage migration inhibitory factor is strong risk factor for young onset of extensive alopecia areata. Genes Immun 2005;6:285-9.
32. Namazi MR, Fallahzadeh MK, Shaghelani H, Sarvestani E. Marked elevation of serum macrophage migration inhibitory factor levels in patients with pemphigus vulgaris. Int J Dermatol 2010;49:146-8.
33. Asano Y, Makino T, Norisugi O, Watanabe H, Abe R, Shimizu H, et al. Macrophage migration inhibitory factor (MIF) in bullous pemphigoid. J Dermatol Sci 2008;49:95-7.
34. Honda A, Abe R, Makino T, Norisugi O, Fujita Y, Watanabe H, et al. Interleukin-1beta and macrophage migration inhibitory factor (MIF) in dermal fibroblasts mediate UVA-induced matrix metalloproteinase-1 expression. J Dermatol Sci 2008;49:63-72.
35. Heise R, Vetter-Kauczok CS, Skazik C, Czaja K, Marquardt Y, Lue H, et al. Expression and Function of Macrophage Migration Inhibitory Factor in the Pathogenesis of UV-induced Cutaneous Non-melanoma Skin Cancer(†). Photochem Photobiol 2012;88:1157-64.
36. Honda A, Abe R, Yoshihisa Y, Makino T, Matsunaga K, Nishihira J, et al. Deficient deletion of apoptotic cells by macrophage migration inhibitory factor (MIF) overexpression accelerates photocarcinogenesis. Carcinogenesis. 2009;30:1597-605.
37. Bifulco C, McDaniel K, Leng L, Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor. Curr Pharm Des. 2008;14:3790-801.
38. Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 1999;264:751-8.
39. Zhao Y, Shimizu T, Nishihira J, Koyama Y, Kushibiki T, Honda A, et al. Tissue regeneration using macrophage migration inhibitory factor-impregnated gelatin microbeads in cutaneous wounds. Am J Pathol 2005;167:1519-29.
40. Abe R, Shimizu T, Ohkawara A, Nishihira J. Enhancement of macrophage migration inhibitory factor (MIF) expression in injured epidermis and cultured fibroblasts. Biochim Biophys Acta 2000;1500:1-9.
41. Gilliver SC, Emmerson E, Bernhagen J, Hardman MJ. MIF: A key player in cutaneous biology and wound healing. Exp Dermatol 2011;20:1-6.
42. Halevy S, Grunwald MH, Sandbank M, Buimovice B, Livni E. Macrophage migration inhibition factor as a diagnostic aid in drug eruptions. Harefuah 1991; 121:147-9.
43. Halevy S, Grunwald MH, Sandbank M, Buimovice B, Joshua H, Livni E. Macrophage migration inhibition factor (MIF) in drug eruption. Arch Dermatol 1990;126:48-51.
44. Cvetkovic I, Stosic-Grujicic S. Neutralization of macrophage migration inhibitory factor-novel approach for the treatment of immunoinflammatory disorders. Int Immunopharmacol 2006;6:1527-34.
45. Shimizu T, Nishihira J, Watanabe H, Abe R, Ishibashi T, Shimizu H. Cetirizine, an H1-receptor antagonist, suppresses the expression of macrophage migration inhibitory factor: its potential anti-inflammatory action. Clin Exp Allergy 2004;34:103-9.
46. Molnar V, Garai J. Plant-derived anti-inflammatory compounds affect MIF tautomerase activity. Int Immunopharmacol 2005;5:849-56.
47. Gilliver SC, Emmerson E, Bernhagen J, Hardman MJ. MIF: A key player in cutaneous biology and wound healing. Exp Dermatol 2011;20:1-6.
48. Stosic-Grujicic S, Stojanovic I, Nicoletti F. MIF in autoimmunity and novel therapeutic approaches. Autoimmun Rev 2009;8:244-9.
49. Morand EF. New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Intern Med J 2005;35:419-26.